MannKind. has filed a patent for a pharmaceutical composition for inhalation containing clofazimine in suspension form. The composition includes specific ingredients for treating pulmonary infections caused by mycobacteria and gram-positive bacteria. The patent also covers the use of clofazimine in aerosol form for pulmonary inhalation. GlobalData’s report on MannKind gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MannKind, Smart inhalers was a key innovation area identified from patents. MannKind's grant share as of January 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
A pharmaceutical composition for treating pulmonary infections caused by mycobacteria or other gram-positive bacteria has been patented. The composition includes clofazimine or its derivative, a nonionic surfactant with a hydrophilic-lipophilic balance value greater than 10, an aqueous liquid carrier, and a mucolytic and/or biofilm destructing agent. The clofazimine is provided in the form of particles with specific size parameters to enhance effectiveness. The composition can be aerosolized for inhalation using various nebulizing devices, ensuring the particles have a mass median aerodynamic diameter of 1 to 5 µm.
Furthermore, the patent covers a method for treating or preventing pulmonary infections by administering the patented composition through inhalation. The method is particularly useful for infections caused by mycobacteria, including nontuberculous mycobacteria and Mycobacterium tuberculosis complex. It is also effective for opportunistic infections in patients with conditions like cystic fibrosis, chronic obstructive pulmonary disease, or acquired immune deficiency syndrome. Additionally, the method allows for the sequential administration of the patented composition with other agents like bedaquiline or amikacin for enhanced therapeutic outcomes in treating pulmonary infections caused by mycobacteria or gram-positive bacteria.
To know more about GlobalData’s detailed insights on MannKind, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
